06:14 , Aug 10, 2018 |  BC Week In Review  |  Company News

Regeneron, bluebird ink multitarget deal for cancer

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
22:43 , Aug 6, 2018 |  BC Extra  |  Company News

Regeneron, bluebird in multitarget cell therapy deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
19:07 , Dec 8, 2017 |  BC Week In Review  |  Company News

bluebird, TC BioPharm in gamma delta CAR T deal

bluebird bio Inc. (NASDAQ:BLUE) and TC BioPharm Ltd. (Edinburgh, U.K.) partnered on Dec. 7 to discover and develop gamma delta chimeric antigen receptor (CAR) T cells to treat hematologic malignancies and solid tumors using TC...
23:58 , Dec 7, 2017 |  BC Extra  |  Company News

bluebird, TC BioPharm in gamma delta CAR T deal

bluebird bio Inc. (NASDAQ:BLUE) and TC BioPharm Ltd. (Edinburgh, U.K.) partnered to discover and develop gamma delta chimeric antigen receptor (CAR) T cells to treat hematologic malignancies and solid tumors using TC BioPharm's ImmuniCAR technology....